CD34 and pneumocystosis: ▪In autoHSCT, prophylaxis is recommended in those receiving myeloablative conditioning regimens, graft manipulations (e.g., CD34 selection), those receiving high-dose glucocorticoids, and those who received purine analog. Prophylaxis is 3–6 months post-autoHSCT or longer for those requiring further immunosuppressives. ▪In alloHSCT recipients, PJP prophylaxis starts after neutrophil engraftment and continues for 6 months, or longer in those on immunosuppression. ▪For PWH, monitoring of CD4+ counts should be followed before discontinuing prophylaxis.